| PERK activation mitigates tau pathology in vitro and in vivo J Bruch, H Xu, TW Rösler, A De Andrade, PH Kuhn, SF Lichtenthaler, ... EMBO molecular medicine 9 (3), 371-384, 2017 | 122 | 2017 |
| Memory deficits correlate with tau and spine pathology in P301S MAPT transgenic mice H Xu, TW Rösler, T Carlsson, A de Andrade, J Bruch, M Höllerhage, ... Neuropathology and applied neurobiology 40 (7), 833-843, 2014 | 59 | 2014 |
| Early neurodegeneration in the brain of a child without functional PKR-like endoplasmic reticulum kinase J Bruch, C Kurz, A Vasiljevic, M Nicolino, T Arzberger, GU Höglinger Journal of Neuropathology & Experimental Neurology 74 (8), 850-857, 2015 | 36 | 2015 |
| Mitochondrial complex 1 inhibition increases 4-repeat isoform tau by SRSF2 upregulation J Bruch, H Xu, A De Andrade, G Höglinger PloS one 9 (11), e113070, 2014 | 26 | 2014 |
| PERK activation mitigates tau pathology in vitro and in vivo. EMBO Mol Med 9: 371–384 J Bruch, H Xu, TW Rösler, A De Andrade, PH Kuhn, SF Lichtenthaler, ... | 6 | 2017 |
| A controller for a miniature intra‐aortic ventricular assist device PL Hsu, J Bruch, R McMahon Artificial Organs 35 (3), 282-287, 2011 | 6 | 2011 |
| A single centre case control study of the efficacy and safety of 5-aminolevulinic acid guided resections of grade IV (WHO) glioblastomas JD Bruch, J Ho, C Watts, SJ Price Neuro-oncology 13, 2-2, 2011 | 3 | 2011 |
| The use of intra-operative carmustine chemotherapy wafers in the management of high grade gliomas: an assessment of complications and access to further therapy J Ho, J Bruch, C Watts, SJ Price NEURO-ONCOLOGY 13, 5-5, 2011 | 1 | 2011 |
| Perk activator for the treatment of neurodegenerative diseases G Höglinger, J Bruch, T Rösler US Patent 10,369,123, 2019 | | 2019 |
| Abstracts from the 2011 BNOS Conference, June 29–July 1, 2011, Homerton College, Cambridge A Fotovati, S Abu-Ali, P Wang, L Deleyrolle, C Lee, J Triscott, J Chen, ... Neuro-oncology 13 (Suppl 2), ii1-ii14, 2011 | | 2011 |
